The GLP-1 Revolution
If you've seen headlines about Ozempic, Wegovy, Mounjaro, or Zepbound in the past two years, you've been watching the GLP-1 revolution unfold in real time. These drugs — all based on peptides that mimic a gut hormone called GLP-1 — represent the most significant advancement in metabolic medicine in decades.
But what actually is GLP-1, how do these drugs work, and how do the three major players differ? Let's break it down.
What Is GLP-1?
GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced by L-cells in your small intestine after you eat. It does three key things [1]:
- Stimulates insulin release from the pancreas (glucose-dependent)
- Suppresses glucagon release, reducing liver glucose output
- Slows gastric emptying and sends satiety signals to the brain
The problem? Natural GLP-1 is broken down by the enzyme DPP-4 within 2-3 minutes. That's where synthetic GLP-1 receptor agonists come in — they're engineered to resist DPP-4 degradation and last for days or weeks.
The Three Major GLP-1 Drugs Compared
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Brand Names | Ozempic®, Wegovy®, Rybelsus® | Mounjaro®, Zepbound® | LY3437943 (Phase 3) |
| Targets | GLP-1 receptor only | GLP-1 + GIP receptors | GLP-1 + GIP + Glucagon receptors |
| Max Weight Loss | ~16.9% (STEP 1) | ~22.5% (SURMOUNT-1) | ~24.2% (Phase 2) |
| FDA Status | Approved (2017/2021) | Approved (2022/2023) | Phase 3 trials |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
Semaglutide — The Pioneer
Semaglutide is a single-target GLP-1 agonist developed by Novo Nordisk. It was the first GLP-1 drug to demonstrate clinically meaningful weight loss in addition to glucose control. The STEP trials showed 16.9% mean weight loss at 68 weeks — groundbreaking at the time [2].
Tirzepatide — The Dual Agonist
Tirzepatide added a second target: GIP (Glucose-dependent Insulinotropic Polypeptide) receptors. The dual mechanism appears to produce additive metabolic effects. In direct comparison (SURPASS-2 trial), tirzepatide demonstrated superior A1C reduction vs. semaglutide [3]. Weight loss data from SURMOUNT-1 showed 22.5% reduction — significantly more than semaglutide [4].
Retatrutide — The Triple Agonist
Retatrutide goes further, adding glucagon receptor activation as a third target. Glucagon raises blood sugar (the opposite of insulin), but it also increases energy expenditure and promotes liver fat oxidation. Phase 2 data showed 24.2% weight loss — the highest ever recorded in a clinical trial [5]. Phase 3 trials are currently underway.
How They Actually Work (Simplified)
All three drugs share the same core mechanism: they mimic GLP-1 to trigger insulin release, suppress appetite, and slow digestion. The differences are in their additional targets:
- Semaglutide: GLP-1 only → Insulin + appetite suppression
- Tirzepatide: GLP-1 + GIP → Enhanced insulin sensitivity + fat metabolism
- Retatrutide: GLP-1 + GIP + Glucagon → All of the above + increased energy expenditure
More targets doesn't always mean better — it also means more complex pharmacology and potentially more side effects. The Phase 3 trial data for retatrutide will be critical to understanding its full safety profile.
The Bigger Picture
Beyond weight loss, these peptide drugs are being investigated for MASH/NASH (liver disease), heart failure, sleep apnea, chronic kidney disease, and substance use disorders. The GLP-1 story is just beginning — and understanding the science behind it is essential for anyone following modern medicine [6].
Sources
- Nauck, M.A. & Meier, J.J. (2018). "Incretin hormones: Their role in health and disease." Diabetes, Obesity and Metabolism, 20(S1), 5-21. PubMed: 29364588
- Wilding, J.P.H. et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM, 384, 989-1002. PubMed: 33567185
- Frías, J.P. et al. (2021). "Tirzepatide versus Semaglutide (SURPASS-2)." NEJM, 385(6), 503-515. PubMed: 34170647
- Jastreboff, A.M. et al. (2022). "Tirzepatide for Obesity (SURMOUNT-1)." NEJM, 387(3), 205-216. PubMed: 35658024
- Jastreboff, A.M. et al. (2023). "Retatrutide for Obesity." NEJM, 389(6), 514-526. PubMed: 37385337
- Drucker, D.J. (2022). "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism, 57, 101351. PubMed: 34626851